Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices 
Asian Currencies Stay Rangebound as Yen Firms on Intervention Talk 
India–U.S. Interim Trade Pact Cuts Auto Tariffs but Leaves Tesla Out 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Strength 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Yen Slides as Japan Election Boosts Fiscal Stimulus Expectations 
Australian Pension Funds Boost Currency Hedging as Aussie Dollar Strengthens 
Namyang Dairy saw a surge in its shares after claiming its Bulgaris yogurt variants can help lower the risk of COVID-19 infection. The company's day trading on Wednesday, April 14, reportedly increased.
As per The Korea Herald, Namyang Dairy’s shares once shot up by 28.68% to KRW489,000 or around $437.39 in the early morning trading. It was added that within 20 minutes after the opening bell, the company’s preferred stocks also surge by the daily allowable limit of 29.78% to reach KRW231,000.
Prior to Wednesday’s results, it was reported that the firm’s shares went up 7.19% and 6.71% on Friday and Monday, respectively. It then increased again by 8.57% on Tuesday, and this shows that Namyang Dairy’s shares have been on the rise since last weekend and continued this week.
Namyang’s COVID-19 claim
Observers are saying that the company’s surge in shares may be due to its claims that its Bulgaris yogurt lineup can help reduce the risk of getting COVID-19. Some market insiders also think that some investors may have also used information that caused the hike in the recent stock tradings.
At any rate, what triggered the sudden increase in shares of Namyang Dairy was the statement given by the company during a news conference in Seoul.
“We’re the first firm in the country that has discovered fermented dairy products are effective in preventing influenza and COVID-19 viruses,” Namyang’s chief of antiviral immune research center, Park Jong Su, said at that time. “Our experiments showed that Bulgaris helped remove the Influenza A (H1N1) virus at a 99.999 percent rate of success, and the COVID-19 at a 77.8 percent success rate.”
He added that the test of the yogurt’s effectiveness in fighting coronavirus was done using the lung cells of a monkey. As a result of this claim, people reportedly rushed out to purchase Namyang Dairy’s Bulgaris yogurts in stores.
Statement from S. Korea’s health officials
After the announcement from Namyang, the public health authorities released a statement. The agency expressed its concern over the claims.
“The latest research result has not proved to be effective in eliminating those viruses in the human body,” the Korea Disease Control and Prevention Agency stated. “Therefore, it is hard to say whether it can serve as an actual prevention or treatment measure for (the viruses).”
